Health Care & Life Sciences » Biotechnology | BioStem Technologies Inc.

BioStem Technologies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2016
2017
Sales/Revenue
607.20
313.40
Cost of Goods Sold (COGS) incl. D&A
394.10
335.70
Gross Income
213.10
22.30
SG&A Expense
3,946.20
4,580.70
EBIT
-
4,603.00
Unusual Expense
153.50
178.80
Non Operating Income/Expense
26.00
1.60
Interest Expense
50.20
33.80
Pretax Income
3,962.70
4,813.90
Consolidated Net Income
3,962.70
4,813.90
Net Income
3,958.00
4,793.10
Net Income After Extraordinaries
3,958.00
4,793.10
Net Income Available to Common
3,958.00
4,793.10
EPS (Basic)
1.12
0.94
Basic Shares Outstanding
3,525.90
5,072.40
EPS (Diluted)
1.12
0.94
Diluted Shares Outstanding
3,525.90
5,072.40
EBITDA
3,570.50
4,416.90
Minority Interest Expense
4.80
20.70

About BioStem Technologies

View Profile
Address
4749 North East, 11th Avenue
Oakland Park Florida 33334
United States
Employees -
Website http://www.biostemtechnologies.com
Updated 07/08/2019
BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. It offers pre-treatment assessment, cell therapies, anti-aging, and wellness compounds. The company was founded by Andrew Smith Van Vurst, Henry W.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.